Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial

被引：0
|
作者：
Ma, Lucy Xiaolu
Titmuss, Emma
Jonker, Derek J.
Kennecke, Hagen Fritz
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aubin, Francine
Koski, Sheryl L.
Tu, Dongsheng
O'Callaghan, Christopher J.
Loree, Jonathan M.
Chen, Eric Xueyu
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Genome Sci Ctr, BCCA, Vancouver, BC, Canada
[3] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[4] Oregon Hlth & Sci Univ, Portland, OR USA
[5] Queens Univ, Kingston, ON, Canada
[6] Hotel Dieu Quebec, CHU Quebec, Quebec City, PQ, Canada
[7] Eastern Hlth, St John, NF, Canada
[8] Juravinski Canc Inst, Hamilton, ON, Canada
[9] Jewish Gen Hosp Sir Mortimer B Davis Jewish Gen H, Montreal, PQ, Canada
[10] Moncton City Hosp, Moncton, NB, Canada
[11] Nova Scotia Canc Care, Halifax, NS, Canada
[12] Hosp Sacr Coeur Montreal, Montreal, PQ, Canada
[13] Hop Charles LeMoyne, St Julie, PQ, Canada
[14] Saskatchewan Canc Agcy, Saskatoon, SK, Canada
[15] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[16] Cross Canc Inst, Edmonton, AB, Canada
[17] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[18] BC Canc Vancouver, Vancouver, BC, Canada
[19] Univ Hlth Network, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3587
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial
    Ma, Lucy Xiaolu
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric X.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
    Ma, Lucy X.
    Titmuss, Emma
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl
    Tu, Dongsheng
    O'Callaghan, Christopher
    Chen, Eric X.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (12)
  • [3] Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
    Ma, Lucy Xiaolu
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 183 - 183
  • [4] Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial
    Wu, Florence T. H.
    Topham, James T.
    O'Callaghan, Christopher J.
    Feilotter, Harriet
    Kennecke, Hagen Fritz
    Banks, Kimberly
    Renouf, Daniel John
    Jonker, Derek J.
    Tu, Dongsheng
    Chen, Eric Xueyu
    Loree, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
    Chen, Eric X.
    Jonker, Derek J.
    Loree, Jonathan M.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice C.
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Chris J.
    JAMA ONCOLOGY, 2020, 6 (06) : 831 - 838
  • [6] Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.
    Chen, Eric Xueyu
    Loree, Jonathan M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Kennecke, Hagen Fritz
    Jonker, Derek J.
    Chaudhary, Ahmad
    Colwell, Bruce
    Harb, Mohammed
    Aucoin, Nathalie
    Couture, Felix
    Samimi, Setareh
    Kavan, Petr
    Aubin, Francine
    Samson, Benoit
    Goffin, John R.
    Berry, Scott
    Abbas, Tahir
    Koski, Sheryl L.
    Wei, Alice Chia-Chi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Impact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
    Loree, J. M.
    Jonker, D. J.
    Feilotter, H.
    Kennecke, H. F.
    Brohawn, P. Z.
    Banks, K.
    Quinn, K.
    Tu, D.
    O'Callaghan, C.
    Chen, E. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 200 - +
  • [8] ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial.
    Topham, James T.
    O'Callaghan, Christopher J.
    Feilotter, Harriet
    Kennecke, Hagen F.
    Lee, Young S.
    Li Weimin
    Banks, Kimberly
    Renouf, Daniel John
    Jonker, Derek
    Tu Dongsheng
    Chen, Eric Xueyu
    Loree, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [9] Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient
    Wu, Florence T. H.
    Topham, James T.
    O'Callaghan, Chris J.
    Feilotter, Harriet
    Kennecke, Hagen F.
    Drusbosky, Leylah
    Renouf, Daniel J.
    Jonker, Derek J.
    Tu, Dongsheng
    Chen, Eric X.
    Loree, Jonathan M.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [10] Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient
    Wu, Florence T. H.
    Topham, James T.
    O'Callaghan, Chris J.
    Feilotter, Harriet
    Kennecke, Hagen F.
    Drusbosky, Leylah
    Renouf, Daniel J.
    Jonker, Derek J.
    Tu, Dongsheng
    Chen, Eric X.
    Loree, Jonathan M.
    JCO PRECISION ONCOLOGY, 2024, 8
12345